Wockhardt gets USFDA nod for generic eye drops

Drug maker Wockhardt has received tentative approval from the US health regulator to market Olopatadine hydrochloride eye drops in the American market. The company has received approval from the US Food and Drug Administration (USFDA) to market 0.1% solution of Olopatadine hydrochloride eye drops, used in treating allergic conjunctivitis. Olopatadine hydrochloride eye drops are the generic equivalent of Alcon Laboratories Inc's Patanol brand.The patent covering this product is under litigation in the US courts and Wockhardt will launch the product after resolution of the same. According to IMS Health data, the total market for Olopatadine in the US is nearly $230 million. Wockhardt is only one of the three companies to receive a tentative approval for this product till date. crackcrack